Status:
TERMINATED
Comparison of Efficacy and Safety of Repaglinide Combined With Insulin NPH Versus Biphasic Human Insulin 30 Alone in Inadequately Controlled Subjects With Type 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
40-75 years
Phase:
PHASE4
Brief Summary
This trial is conducted in Europe. The aim of this trial is to compare the efficacy and safety of repaglinide combined with insulin NPH versus biphasic human insulin 30 alone in type 2 diabetics inade...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- HbA1c: 7.5-11.0% on current therapy
- OHA (oral hypoglycaemic agent) treatment for a minimum of two years
- BMI (body mass index): 25-32 kg/m2
Exclusion
Key Trial Info
Start Date :
September 16 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 20 2004
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00799448
Start Date
September 16 2003
End Date
September 20 2004
Last Update
February 20 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Athens, Greece, 15127